Readoutin 14d
Suven Life Sciences Limited — Masupirdine 50 mg
Phase 3 primary completion: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Agitation
Readoutin 14d
Phase 3 primary completion: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.